Concepedia

Author

K. Govind Babu

Kidwai Memorial Institute of Oncology

Also Known As

K G Babu, K Govind Babu, K. Babu, K. G. Babu, K. Govind Babu, K.G. Babu, KG Babu, KGovind Babu

48

Publications

603

Citations

12

H-Index

39

Concepts

All Affiliations

Kidwai Memorial Institute of OncologyNational Taiwan University HospitalUniversity of MalayaCharité - Universitätsmedizin BerlinSt James's University Hospital
KG

About

K. Govind Babu is an author at Kidwai Memorial Institute of Oncology specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

266

2

Health Sciences

3

3

107

3

Blood Transplantation

1

1

12

4

Head And Neck Surgery

1

1

109

5

Immunology

1

1

38

K. Govind Babu

×

14

Publications

502

Citations

12

H-Index

YearCitations

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

K. Park, Johan Vansteenkiste, Ki Hyeong Lee,

Annals of Oncology

2020

111

Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients

Balaswamy Reddy, V. Lokesh, M. S. Vidyasagar,

Oral Oncology

2014

109

Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial

Jörge E. Cortes, Cármino Antônio De Souza, Manuel Ayala,

The Lancet Haematology

2016

40

Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1

Eugen Tausch, Philipp Beck, Richard F. Schlenk,

Haematologica

2020

38

An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): Four-year survival results from a phase IIb study.

K. Govind Babu, Lokesh Viswanath, Balaswamy Reddy,

Journal of Clinical Oncology

2010

37

Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib

Debu Tripathy, Seock‐Ah Im, Marco Colleoni,

Cancer Research

2021

30

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer

Smruti Koppikar, Ana Oaknin, K. Govind Babu,

ESMO Open

2023

27

Induction chemotherapy in technically unresectable locally advanced T4a oral cavity squamous cell cancers: Experience from a regional cancer center of South India

Tamojit Chaudhuri, A.H. Rudresha, KC Lakshmaiah,

Indian Journal of Medical and Paediatric Oncology

2017

22

Correlation of BMI with breast cancer subtype and tumour size

K. Govind Babu, Abhishek Anand, K C Lakshmaiah,

ecancermedicalscience

2018

19

Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL

Peter Hillmen, Ann Janssens, K. Govind Babu,

Acta Oncologica

2016

17

Page 1